# US 2022/0031820 A1 · Modulation of granzyme k activity in the treatment of skin conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031820 A1
- Document ID: US20220031820A1
- Status: Published application
- Kind: A1
- Application number: 17/279,442
- Filed: 2019-09-24
- Published: 2022-02-03
- Earliest claimed: 2018-09-24
- Assignees: The University of British Columbia
- Applicants: The University of British Columbia
- Inventors: David J. GRANVILLE; Christopher TURNER; Matthew ZEGLINSKI; Katlyn RICHARDSON; Sho HIROYASU
- Web page: https://patentgrep.com/patent/US20220031820A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- C07K 14/8114: {Kunitz type inhibitors}
- C12N 9/6467: {Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)}
- C12Q 1/37: involving peptidase or proteinase
- G01N 2333/96436: Granzymes
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N 2800/205: Scaling palpular diseases, e.g. psoriasis, pytiriasis
- G01N 2800/7095: Inflammation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods for treating inflammatory skin conditions, such as atopic dermatitis and psoriasis, and for promoting skin wound healing and for treating skin wounds, such as thermal and pressure injury, by reducing the activity of Granzyme K.

## Claims

### Claim 1

A method of treating an inflammatory skin condition in a subject, comprising reducing the activity of Granzyme K in a subject, thereby treating the inflammatory skin condition.

### Claim 2 (depends on 1)

The method of claim 1, wherein the inflammatory skin condition is psoriasis or atopic dermatitis.

### Claim 3

A method of treating a wound in a subject, comprising reducing the activity of Granzyme K in a subject, thereby treating the wound.

### Claim 4 (depends on 3)

The method of claim 3, wherein the wound is a burn wound, chronic wound, acute wound, pressure injury, or ischemic injury.

### Claim 5 (depends on 4)

The method of claim 4, wherein the pressure injury is ischemia reperfusion injury.

### Claim 6 (depends on 1)

The method of claim 1, wherein reducing the activity of Granzyme K comprises administering an effective amount of a Granzyme K inhibitor to the subject.

### Claim 7 (depends on 6)

The method of claim 6, wherein the Granzyme K inhibitor is a small molecule, a nucleic acid molecule, a peptide, or an antibody.

### Claim 8 (depends on 6)

The method of claim 6, wherein the Granzyme K inhibitor is an inter-alpha inhibitor protein (IαIp).

### Claim 9 (depends on 6)

The method of claim 6, wherein the Granzyme K inhibitor is bikunin.

### Claim 10

A method of treating an inflammatory skin condition in a subject, comprising administering an effective amount of a Granzyme K inhibitor to the subject, thereby treating the inflammatory skin condition.

### Claim 11 (depends on 10)

The method of claim 10, wherein the inflammatory skin condition is psoriasis or atopic dermatitis.

### Claim 12

A method of treating a wound in a subject, comprising administering an effective amount of a Granzyme K inhibitor to the subject, thereby treating the wound.

### Claim 13 (depends on 12)

The method of claim 12, wherein the wound is a burn wound, acute wound, chronic wound, pressure injury, or ischemic injury.

### Claim 14 (depends on 13)

The method of claim 13, wherein the pressure injury is ischemia reperfusion injury.

### Claim 15 (depends on 10)

The method of claim 10, wherein the Granzyme K inhibitor is a small molecule, a nucleic acid molecule, a peptide, or an antibody.

### Claim 16 (depends on 10)

The method of claim 10, wherein the Granzyme K inhibitor is an inter-alpha inhibitor protein (IαIp).

### Claim 17 (depends on 10)

The method of claim 10, wherein the Granzyme K inhibitor is bikunin.

### Claim 18

A method of promoting wound healing in a subject, comprising inhibiting cleavage of syndecan-1 in keratinocytes by reducing the activity of Granzyme K in the subject.

### Claim 19

A method of promoting wound healing in a subject, comprising reducing pro-inflammatory cytokine response in keratinocytes, fibroblasts, macrophages, and/or endothelial cells by reducing the activity of Granzyme K in the subject.

### Claim 20

A method for promoting wound re-epithelization, comprising reducing the activity of Granzyme K in keratinocytes proximate to the wound.

### Claim 21

A method of promoting wound healing in a subject, comprising inhibiting cleavage of syndecan-1 by administering an effective amount of Granzyme K inhibitor to the subject.

### Claim 22

A method of promoting wound healing in a subject, comprising reducing pro-inflammatory cytokine response in keratinocytes, fibroblasts, macrophages, and/or endothelial cells by administering an effective amount of Granzyme K inhibitor to the subject.

### Claim 23

A method for promoting wound re-epithelization in a subject, comprising inhibiting cleavage of syndecan-1 in a keratinocyte by administering an effective amount of Granzyme K inhibitor to the subject.

### Claim 24

A method for promoting wound re-epithelization in a subject, comprising administering an effective amount of Granzyme K inhibitor to the subject.

### Claim 25 (depends on 18)

The method of claim 18, wherein the wound is a burn wound, chronic wound, acute wound, pressure injury, or ischemic injury.

### Claim 26 (depends on 21)

The method of claim 21, wherein the inhibitor is administered topically or systemically.

### Claim 27 (depends on 21)

The method of claim 21, wherein the Granzyme K inhibitor is a small molecule, a nucleic acid molecule, a peptide, or an antibody.

### Claim 28 (depends on 21)

The method of claim 21, wherein the Granzyme K inhibitor is an inter-alpha inhibitor protein (IαIp).

### Claim 29 (depends on 21)

The method of claim 21, wherein the Granzyme K inhibitor is bikunin.

### Claim 30

A method of stimulating re-epithelialization, comprising inhibiting syndecan-1 cleavage in the keratinocyte by reducing the activity of GzmK in the wounded or damaged tissue area.

### Claim 31

A method of converting a pro-inflammatory phenotype to a pro-healing wound repair phenotype, comprising reducing pro-inflammatory cytokine responses in keratinocytes, fibroblasts, macrophages, and/or endothelial cells by reducing the activity of GzmK in the wounded or damaged tissue area.

### Claim 32

A method for screening a candidate compound for its ability to treat an inflammatory skin condition or to promote wound healing, comprising contacting the candidate compound with Granzyme K in vitro, wherein inhibition of Granzyme K activity compared to Granzyme K that has not been contacted with the candidate compound indicates that the candidate compound is a compound that may be useful for the treatment of the inflammatory skin condition or wound.

### Claim 33 (depends on 32)

The method of claim 32, wherein the candidate compound selectively inhibits GzmK and does not substantially inhibit GzmA at the same compound concentration.
